Merus NV (MRUS): Market Cap to Revenue

Brandmark of Merus Corp (MRUS)

A stable staff of R&D specialists ensures scientific progress for Merus N.V., which is reflected in the price action after verifying the current P/S ratio on GURU.Markets. The value of 120.90 reflects the metric's balance while the company utilizes outsourced production via CMOs and protects its unique molecules with stringent FDA patents, creating a legal barrier for competitors in the treatment of female oncological diseases.

MRUS merus.nl Price-to-Revenue Ratio (07/04/2022 - 01/10/2026)

Metric breakdowns and analytics for Merus Corp (MRUS)

- stock price and consensus target price:
Share Price merus.nl|MRUS - Price Target Chart
- stock exchange capitalization data:
Market Valuation Merus Corp|MRUS - Enterprise Value
- book value of equity indicators:
Net Asset Value per Share Merus|MRUS - Company Book Value|Market Value to Book Value merus.nl|MRUS - Cumulative Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Merus N.V.|MRUS - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Merus Therapeutics|MRUS - Company Total Debt|Debt to Net Assets Ratio Merus Corp|MRUS - Company Long-Term Debt|Company Short-Term Indebtedness Merus|Interim Coverage Ratio merus.nl
- earnings and multiples data:
MRUS - Net Income|Expected Profit Merus N.V.|MRUS - Price to Earnings Ratio|Market Cap to Projected Earnings Merus NV|MRUS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Merus Corp|MRUS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Merus|MRUS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth merus.nl|MRUS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Merus N.V.
- total revenue and sales volume data:
MRUS - Revenue and Sales Volume|Company Future Sales Volume merus.nl|MRUS - P/S Multiple|Forward P/S Multiple Merus Corp
Summary company analytics:merus.nl, MRUS
Signature product of Merus N.V.

The P/S multiple allows for an assessment of an asset's investment value through the ratio of market capitalization to annual revenue, revealing the extent of overpayment for a business in a high-cost-of-capital environment. This price-to-sales trend reflects market expectations regarding the scaling of the Merus N.V. (MRUS) bispecific antibody platform and the potential for future partnerships with biopharmaceutical behemoths during the clinical expansion phase.

Competitors of Merus N.V.

immutep.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Anixa ANIX|ATOS - Market Cap to Revenue|Context Tx - P/S Multiple|Price to Sales Mersana Therapeutics|BriaCell Therapeutics (BCTX) - Price-to-Revenue Ratio|ESSA Pharma - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue QTI